An open-label, first-in-human, dose escalation study of a novel CD3-CD123 bispecific T-cell engager administered as a single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high risk myelodysplastic syndrome.

被引：4

作者：

Boissel, Nicolas

de Botton, Stephane

Thomas, Xavier G.

Rao, Ercole

Bonnevaux, Helene

Rubin-Carrez, Chantal

Guerif, Stephane

Beys, Eric

Gosselin, Alice

Bauchet, Anne-Laure

Novikov, Valery

Fernandes, Elma

Wiederschain, Dmitri

Palatinsky, Emanuel A.

Hsu, Karl

Fraenkel, Paula Goodman

机构：

[1] Hop St Louis, Paris, France

[2] Inst Gustave Roussy, INSERM, U1170, Villejuif, France

[3] Ctr Hosp Lyon Sud, Lyon, France

[4] Sanofi, Frankfurt, Germany

[5] Sanofi, Vitry Sur Seine, France

[6] Sanofi, Alfortville, France

[7] Sanofi, Bridgewater, NJ USA

[8] Sanofi, Cambridge, MA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.TPS7076

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS7076

引用

页数：1

共 50 条

[1] A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia.
Stein, Anthony Selwyn
Jongen-Lavrencic, Mojca
Garciaz, Sylvain
Huls, Gerwin A.
Maiti, Abhishek
Boissel, Nicolas
De Botton, Stephane
Fleming, Shaun
Zwaan, C. Michel
de Leeuw, David C.
Desai, Pinkal
Arellano, Martha Lucia
Avigan, David
Langemeijer, Saskia
Jensen, Kyle A.
Wagenaar, Timothy
Mi, Gu
Abbadessa, Giovanni
Bajel, Ashish
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)
Stein, Anthony S.
Bajel, Ashish
Fleming, Shaun
Jongen-Lavrencic, Mojca
Garciaz, Sylvain
Maiti, Abhishek
Boissel, Nicolas
De Botton, Stephane
Huls, Gerwin A.
de Leeuw, David C.
Avigan, David
Jensen, Kyle
Demers, Brigitte
Wagenaar, Timothy
Mi, Gu
Ziti-Ljajic, Samira
Draganov, Dobrin
Abbadessa, Giovanni
Wei, Andrew H.
BLOOD, 2022, 140 : 7476 - 7477
[3] First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High RiskMyelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics
Bajel, Ashish
Garciaz, Sylvain
Desai, Pinkal
Huls, Gerwin A.
Maiti, Abhishek
Jongen-Lavrencic, Mojca
Boissel, Nicolas
De Botton, Stephane
de Leeuw, David C.
Fleming, Shaun
Zwaan, C. Michel
Arellano, Martha
Avigan, David
Saultz, Jennifer N.
Mantzaris, Ioannis
Jensen, Kyle
Wagenaar, Timothy
Mi, Gu
Ziti-Ljajic, Samira
Draganov, Dobrin
Abbadessa, Giovanni
Stein, Anthony Selwyn
BLOOD, 2023, 142
[4] A first-in-human, phase 1, dose escalation study of SGR-2921 as monotherapy in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.
Weiss, Daniel
Dinardo, Courtney Denton
Strickland, Stephen Anthony
Skikne, Barry
Zeidan, Amer Methqal
Traer, Elie A.
Carraway, Hetty E.
Carraway, Hetty E.
Frankel, Stanley R.
Wang, Jacky
Pirie-Shepherd, Steven Robert
Piccotti, Joseph R.
Wright, Duncan Hamish
Akinsanya, Karen
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] A First-in-Human Study of CD123 Natural Killer Cell Engager (NKCE) SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-Myelodysplasia (HR-MDS)
Stein, Anthony
Lavrencic, Mojca
Garciaz, Sylvain
Huls, Gerwin
Maiti, Abhishek
Boissel, Nicolas
Botton, Stephane
Fleming, Shaun
Zwaan, Michel
de Leeuw, David C.
Desai, Pinkal
Arellano, Martha
Avigan, David
Langemeijer, Saskia
Jensen, Kyle
Wagenaar, Timothy
Mi Gu
Abbadessa, Giovanni
Bajel, Ashish
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S3 - S4
[6] First-in-human study of JNJ-67571244, a CD33 x CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome
Narayan, Rupa
Pierola, Ana Alfonso
Donnellan, William B.
Yordi, Antonieta Molero
Abdul-Hay, Maher
Platzbecker, Uwe
Subklewe, Marion
Kadia, Tapan Mahendra
Alonso-Dominguez, Juan Manuel
McCloskey, James
Bradford, Kathryn
Curtis, Martin
Daskalakis, Nikki
Guttke, Christina
Safer, Karim
Hiebert, Brett
Murphy, Joseph
Li, Xiang
Duchin, Ken
Esteban, Daniel
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (03):
[7] Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Westervelt, Peter
Cortes, Jorge E.
Altman, Jessica K.
Long, Meixiao
Oehler, Vivian G.
Gojo, Ivana
Guenot, Jeanmarie
Chun, Patrick
Roboz, Gail J.
BLOOD, 2019, 134
[8] Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Westervelt, Peter
Roboz, Gail J.
Cortes, Jorge E.
Kantarjian, Hagop M.
Lee, Sangmin
Rettig, Michael P.
Han, Tae H.
Guenot, Jeanmarie
Feldman, Eric J.
DiPersio, John F.
BLOOD, 2018, 132
[9] A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Ravandi, Farhad
Stein, Anthony S.
Kantarjian, Hagop M.
Walter, Roland B.
Paschka, Peter
Jongen-Lavrencic, Mojca
Ossenkoppele, Gert J.
Yang, Zhao
Mehta, Bhakti
Subklewe, Marion
BLOOD, 2018, 132
[10] A phase 1 study of CD38-bispecific antibody (XmAb18968) for patients with CD38 expressing relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
Murthy, Guru Subramanian Guru
Kearl, Tyce
Cui, Weigo
Johnson, Bryon
Hoffmeister, Karin
Harrington, Alexandra
Szabo, Aniko
Badar, Talha
Duvall, Adam
Leonard, Jessica Taft
Yi, Cecilia Ysabel Arana
Baim, Arielle
Yaghoubi, Shahriar
Shah, Bijal D.
Stock, Wendy
Atallah, Ehab L.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →